New liquid oral formulations of hydroxychloroquine: a physicochemical stability study
Hydroxychloroquine (HCQ) presents many drug properties that increase its therapeutic use. There are, indeed, different research pathways in numerous autoimmune, inflammatory, and infectious diseases, as well as in cancerology. HCQ is only marketed as HCQ sulfate in film-coated or coated tablets for...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2021-03-01
|
Series: | Pharmaceutical Technology in Hospital Pharmacy |
Subjects: | |
Online Access: | https://doi.org/10.1515/pthp-2020-0013 |
id |
doaj-561c3cf312b54639b970bc2690cacafe |
---|---|
record_format |
Article |
spelling |
doaj-561c3cf312b54639b970bc2690cacafe2021-10-03T07:42:43ZengDe GruyterPharmaceutical Technology in Hospital Pharmacy2365-24112365-242X2021-03-01614596710.1515/pthp-2020-0013New liquid oral formulations of hydroxychloroquine: a physicochemical stability studyLebreton Vincent0Bourcier Blandine1Cosson Karine2Lagarce Frédéric3Spiesser-Robelet Laurence4Vrignaud Sandy5Pharmacie Centrale, Centre Hospitalier Universitaire d’Angers, Angers Cedex, FrancePharmacie Centrale, Centre Hospitalier Universitaire d’Angers, Angers Cedex, FrancePharmacie Centrale, Centre Hospitalier Universitaire d’Angers, Angers Cedex, FrancePharmacie Centrale, Centre Hospitalier Universitaire d’Angers, Angers Cedex, FrancePharmacie Centrale, Centre Hospitalier Universitaire d’Angers, Angers Cedex, FrancePharmacie Centrale, Centre Hospitalier Universitaire d’Angers, Angers Cedex, FranceHydroxychloroquine (HCQ) presents many drug properties that increase its therapeutic use. There are, indeed, different research pathways in numerous autoimmune, inflammatory, and infectious diseases, as well as in cancerology. HCQ is only marketed as HCQ sulfate in film-coated or coated tablets for oral use. No pediatric liquid form is currently available on the market. The purpose of the present study is to develop oral liquid formulations for HCQ at 50 mg/mL with two different oral vehicle suspensions, namely ORA-Plus®/ORA-Sweet® (ORA) and Syrspend® SF PH 4 (SYR).https://doi.org/10.1515/pthp-2020-0013an antimalarial agenthplchydroxychloroquine sulfateoral suspensionstability study |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lebreton Vincent Bourcier Blandine Cosson Karine Lagarce Frédéric Spiesser-Robelet Laurence Vrignaud Sandy |
spellingShingle |
Lebreton Vincent Bourcier Blandine Cosson Karine Lagarce Frédéric Spiesser-Robelet Laurence Vrignaud Sandy New liquid oral formulations of hydroxychloroquine: a physicochemical stability study Pharmaceutical Technology in Hospital Pharmacy an antimalarial agent hplc hydroxychloroquine sulfate oral suspension stability study |
author_facet |
Lebreton Vincent Bourcier Blandine Cosson Karine Lagarce Frédéric Spiesser-Robelet Laurence Vrignaud Sandy |
author_sort |
Lebreton Vincent |
title |
New liquid oral formulations of hydroxychloroquine: a physicochemical stability study |
title_short |
New liquid oral formulations of hydroxychloroquine: a physicochemical stability study |
title_full |
New liquid oral formulations of hydroxychloroquine: a physicochemical stability study |
title_fullStr |
New liquid oral formulations of hydroxychloroquine: a physicochemical stability study |
title_full_unstemmed |
New liquid oral formulations of hydroxychloroquine: a physicochemical stability study |
title_sort |
new liquid oral formulations of hydroxychloroquine: a physicochemical stability study |
publisher |
De Gruyter |
series |
Pharmaceutical Technology in Hospital Pharmacy |
issn |
2365-2411 2365-242X |
publishDate |
2021-03-01 |
description |
Hydroxychloroquine (HCQ) presents many drug properties that increase its therapeutic use. There are, indeed, different research pathways in numerous autoimmune, inflammatory, and infectious diseases, as well as in cancerology. HCQ is only marketed as HCQ sulfate in film-coated or coated tablets for oral use. No pediatric liquid form is currently available on the market. The purpose of the present study is to develop oral liquid formulations for HCQ at 50 mg/mL with two different oral vehicle suspensions, namely ORA-Plus®/ORA-Sweet® (ORA) and Syrspend® SF PH 4 (SYR). |
topic |
an antimalarial agent hplc hydroxychloroquine sulfate oral suspension stability study |
url |
https://doi.org/10.1515/pthp-2020-0013 |
work_keys_str_mv |
AT lebretonvincent newliquidoralformulationsofhydroxychloroquineaphysicochemicalstabilitystudy AT bourcierblandine newliquidoralformulationsofhydroxychloroquineaphysicochemicalstabilitystudy AT cossonkarine newliquidoralformulationsofhydroxychloroquineaphysicochemicalstabilitystudy AT lagarcefrederic newliquidoralformulationsofhydroxychloroquineaphysicochemicalstabilitystudy AT spiesserrobeletlaurence newliquidoralformulationsofhydroxychloroquineaphysicochemicalstabilitystudy AT vrignaudsandy newliquidoralformulationsofhydroxychloroquineaphysicochemicalstabilitystudy |
_version_ |
1716845807494234112 |